Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

PHASE2UnknownINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2010

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

bortezomib

DRUG

dexamethasone

DRUG

pegylated liposomal doxorubicin hydrochloride

GENETIC

protein analysis

OTHER

immunologic technique

Trial Locations (12)

10595

New York Medical College, Valhalla

20817

Center for Cancer and Blood Disorders, Bethesda

29403

Charleston Hematology Oncology Associates, PA, Charleston

85712

Arizona Clinical Research Center, Incorporated, Tucson

90057

Oncology Care Medical Associates - San Gabriel, Los Angeles

90069

James R. Berenson MD, Incorporated, West Hollywood

92025

San Diego Pacific Oncology and Hematology Associates, Incorporated - Escondido, Escondido

92270

Desert Cancer Care, Rancho Mirage

92354

Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda

93105

Santa Barbara Hematology Oncology Medical Group at Cancer Center of Santa Barbara, Santa Barbara

95661

Sutter Cancer Center at Roseville Medical Center, Roseville

93309-0633

Comprehensive Blood and Cancer Center, Bakersfield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oncotherapeutics

INDUSTRY